- Telehealth visits
Elliot Stieglitz, MD
Hematology and Medical Oncology • Medical Oncology- Telehealth visits
Elliot Stieglitz, MD
Hematology and Medical Oncology • Medical Oncology- Telehealth visits
On this page
About me
Dr. Elliot Stieglitz is a pediatric hematologist-oncologist who cares for children with difficult-to-treat leukemias (blood cancers most often involving white blood cells).
Stieglitz's laboratory research focuses on juvenile myelomonocytic leukemia (JMML), which is often difficult to diagnose and treat. His research has found that the course of JMML varies among patients and that DNA profiling can predict which patients will benefit from certain new treatments. He leads clinical trials – studies that evaluate new therapies – of targeted treatments for patients with JMML, and his research has received funding from the National Institutes of Health, V Foundation, Pediatric Cancer Research Foundation, Cancer League, St. Baldrick's Foundation and Alex's Lemonade Stand Foundation.
Stieglitz earned his medical degree from the Renaissance School of Medicine at Stony Brook University. He completed a residency in pediatrics at New York – Presbyterian Weill Cornell Medical Center and a fellowship in pediatric hematology-oncology at UCSF.
Education & training
Board certification
- Pediatric Hematology-Oncology, American Board of Pediatrics
- Pediatrics, American Board of Pediatrics
Fellowship
- Ped. Hema/Oncology, UCSF School of Medicine -GME
Residency
- Pediatrics, New York Presbyterian Hospital - Weill Cornell
Degree
- MD, State Univ of NY at Stony Brook School of Medicine
Academic Title
- Clinical Professor
My expertise
Specialties
- Hematology and Medical Oncology
- Medical Oncology
- Pediatric Hematology-Oncology
My research
Clinical trials
Venetoclax Basket Trial for High Risk Hematologic MalignanciesOpens in a new window
Recruiting
To determine the maximum tolerated dose (MTD of venetoclax given in combination with regimen-prescribed chemotherapy. The MTD is defined as the dose level asso...A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiaOpens in a new window
Recruiting
The incidence of dose limiting toxicities (DLTs) after the 1st course of therapy will be measured at different dose levels.
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.